It has been proposed that a change in subtype for Luminal type tumours may be as a consequence of this ER-HER2 receptor cross-talk, where ER expression can limit PI3K pathway activity affecting HER2 pathway activation, whilst HER2 overexpression, largely due to copy number amplification, can lead to loss of ER gene expression. Here, ERBB2 is linked to neoplasm.